The cash runway through Q1 2027 provides limited visibility for a pre-revenue biotech. The upcoming EASL presentations on May 30, 2026 and any partnering announcements are the key near-term catalysts. Monitor for partnership deal terms that could extend runway and validate the PSC/IBD thesis.
CMMB drugs
CMMB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $1.70entry
- T+1 · 6mo ago −2.35%α −1.13% · $1.66
- T+5 · 6mo ago +7.06%α +7.78% · $1.82
- T+20 · 5mo ago −2.94%α −2.08% · $1.65
- T+60 · 3mo ago +11.18%α +7.59% · $1.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab Therapeutics reported Q1 2026 financial results, with net loss narrowing to $1.8M from $3.3M YoY on lower R&D spend as the Phase 2 SPRING trial winds down. Cash of $8.0M funds operations through Q1 2027. The company highlighted new biomarker data from nebokitug in PSC suggesting potential benefit in PSC patients with co-existing IBD, and continues to advance partnering discussions.
Key Facts
- Net loss of $1.8M in Q1 2026 vs $3.3M in Q1 2025
- Cash, cash equivalents and short-term bank deposits of $8.0M as of March 31, 2026
- Cash runway expected to fund operations through end of Q1 2027
- R&D expenses decreased to $0.9M from $2.5M YoY due to winding down of Phase 2 SPRING trial
- 576,030,200 ordinary shares outstanding as of March 31, 2026 (7,200,377 ADSs)
- New biomarker data from SPRING trial presented at DDW 2026 and upcoming EASL 2026 shows nebokitug modulates pathways relevant to both PSC and IBD
- Company continues to advance multiple partnering options for nebokitug
Financial Impact
Net loss improved by $1.5M YoY to $1.8M; cash burn of $2.4M in Q1 2026
Risk Factors
- Cash runway only through Q1 2027, financing risk if partnering discussions fail to materialize
- No revenue and pre-commercial stage, binary risk on Phase 3 trial outcomes
- Biomarker data is correlative, not proof of clinical efficacy in IBD co-morbidity
- Small market cap ($13M) amplifies volatility on any news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002672 |
| Document: zk2635329.htm | 0001178913-26-002672 |
| Document: 0001178913-26-002672-index-headers.html | 0001178913-26-002672 |
| Document: 0001178913-26-002672-index.html | 0001178913-26-002672 |
| Document: 0001178913-26-002672.txt | 0001178913-26-002672 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers